Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

PARSIPPANY, N.J., Feb. 19, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today reported net revenue increased 13 percent to $1.75 billion for the fourth quarter 2012, compared to $1.54 billion in the fourth quarter 2011. On a non-GAAP basis, diluted earnings per share for the fourth quarter 2012 was $1.59, compared to $1.77 per diluted share in the fourth quarter 2011, a decline of 10%.  GAAP earnings per diluted share for the fourth quarter 2012 were $0.21, compared to $0.75 in the prior year period. Fourth quarter 2011 earnings includes the launch of generic Lipitor® which contributed $0.64 of non-GAAP earnings per diluted share to the prior-year period compared to $0.03 in the fourth quarter of 2012. 

For the fourth quarter 2012, adjusted EBITDA was $393.0 million, compared to $393.4 million for the fourth quarter 2011.
Cash and marketable securities were $328.0 million as of December 31, 2012.

For the full year 2012, net revenue increased 29 percent to $5.9 billion, compared to net revenue of $4.6 billion for full year 2011.  On a non-GAAP basis, 2012 earnings per diluted share increased 26% to $6.00 per diluted share compared $4.77 per diluted share in 2011. GAAP earnings per diluted share were $0.76 for the full year 2012, compared to $2.06 in 2011. Adjusted EBITDA for the full year 2012 increased 26 percent to $1.4 billion, compared to full year 2011 adjusted EBITDA of $1.1 billion. Cash flow from operations was $665.8 million.

Fourth quarter and full year 2012 results for Actavis, Inc. include results of legacy Actavis as of November 1, 2012. Refer to the attached reconciliation tables for adjustments to GAAP earnings.

"With the close of the Actavis acquisition and combination of our two companies, under our new global name, Actavis, Inc., we are beginning 2013 on a solid commercial and financial foundation, well-pos
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ( http://www.researchandmarkets.com/research/vzhr6h/video ) has announced the addition of ... Growth, Trends and Forecast 2014 - 2020" report to ... of fascination since the era of the cold war between ... Russia. Earlier even a small glimpse of human form was ...
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... 2012  The use of an injectable, clot-preventing drug known ... advanced cancer complicated by blood clots increased steadily between ... in The Oncologist , funded by the National ... despite previous research indicating LMWH is the preferred first-line ...
... 2012  MolecularHealth, Inc., a leader in clinico-molecular informatics™, ... collaboration agreement with the U.S. Food and Drug ... Molecular Analysis of Side Effects (MASE), a ... assessment and prediction. The FDA,s Center ...
Cached Medicine Technology:Injectable Treatment for Blood Clots in Advanced Cancer Patients Increases, According to New Research 2Injectable Treatment for Blood Clots in Advanced Cancer Patients Increases, According to New Research 3MolecularHealth and FDA to Collaborate on Analytical Tools for Mechanism-Based Drug Safety Assessment 2
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 The US represents ... this report. In 2013, GlobalData’s forecast estimates that sales of ... CRC market due to the high incidence of the disease, ... the 5EU, Japan, and China. Increased sales of CRC therapies ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... study, as the demand for facial cosmetic surgery has increased, ... never been more popular. Most products go down in price ... looked at how cosmetic surgery, as a product//, has performed ... surveyed 1,600 members of the American Academy of Facial Plastic ...
... Abbott Laboratories said it has agreed to acquire the ... million in cash. Abbott said the deal will strengthen ... presence in the vascular business for polymer-coated stents - ... ,Abbott has been the exclusive U.S. distributor of ...
... relatively small number of mutations which can be detected by ... actually more genetically stable than some adult cells. ,Jay A. ... the study, everybody has assumed that the embryonic stem cell ... lower than what you find in the adult cells.// Peter ...
... Researchers at the Country University of Chicago, have ... expensive, broad-spectrum antibiotic, Azithromycin, which is commonly prescribed ... benefit.// ,They arbitrarily allocated 150 adults with ... C. All patients got cough syrup (liquid dextromorphan) ...
... using different sets of glasses to see and read far ... glasses and contact lens, was laser surgery. Researchers at Mt. ... because it was a non-laser treatment for people who were ... procedure for far-sightedness. And unlike laser treatments, there’s no need ...
... According to a new review of the medical proof, the ... ulcers. Venous leg ulcers are caused by poor circulation and ... Standard treatment is by compression stretch bandages, but up to ... year of this treatment.// ,Doctors at the University ...
Cached Medicine News:Health News:Stem Cells Have Few Mutations 2
ThermalSeal RT (2mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates....
DMSO-resistant microplate sealing film...
Sealing tape, white Rayon, breathable, NS...
Sealing tape, slightly stiffer than Polyolefin tape. Certified RNase and DNase free....
Medicine Products: